Skip to main content
PMC home page
Annals of Surgery logoLink to Annals of Surgery
. 1996 Sep;224(3):288–296. doi: 10.1097/00000658-199609000-00005

Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.

D J Sugarbaker 1, J P Garcia 1, W G Richards 1, D H Harpole Jr 1, E Healy-Baldini 1, M M DeCamp Jr 1, S J Mentzer 1, M J Liptay 1, G M Strauss 1, S J Swanson 1
PMCID: PMC1235368  PMID: 8813257

Abstract

OBJECTIVE: The authors examine the feasibility and efficacy of trimodality therapy in the treatment of malignant pleural mesothelioma and identify prognostic factors. BACKGROUND: Mesothelioma is a rare, uniformly fatal disease that has increased in incidence in recent decades. Single and bimodality therapies do not improve survival. METHODS: From 1980 to 1995, 120 patients underwent treatment for pathologically confirmed malignant mesothelioma at Brigham and Women's Hospital and Dana-Farber Cancer Institute (Boston, MA). Initial patient evaluation was performed by a multimodality team. Patients meeting selection criteria and with resectable disease identified by computed tomography scan or magnetic resonance imaging underwent extrapleural pneumonectomy followed by combination chemotherapy and radiotherapy. RESULTS: The cohort included 27 women and 93 men with a mean age of 56 years. Operative mortality rate was 5.0%, with a major morbidity rate of 22%. Overall survival rates were 45% at 2 years and 22% at 5 years. Two and 5-year survival rates were 65% and 27%, respectively, for patients with epithelial cell type, and 20% and 0%, respectively, for patients with sarcomatous or mixed histology tumors. Nodal involvement was a significant negative prognostic factor. Patients who were node negative with epithelial histology had 2- and 5-year survival rates of 74% and 39%, respectively. Involvement of margins at time of resection did not affect survival, except in the case of full-thickness, transdiaphragmatic invasion. Classification on the basis of a revised staging system stratified median survivals, which were 22, 17, and 11 months for stages I, II, and III, respectively (p = 0.04). CONCLUSIONS: Extrapleural pneumonectomy with adjuvant therapy is appropriate treatment for selected patients with malignant mesothelioma selected using a revised staging system.

Full text

PDF
288

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen K. B., Faber L. P., Warren W. H. Malignant pleural mesothelioma. Extrapleural pneumonectomy and pleurectomy. Chest Surg Clin N Am. 1994 Feb;4(1):113–126. [PubMed] [Google Scholar]
  2. Antman K. H., Blum R. H., Greenberger J. S., Flowerdew G., Skarin A. T., Canellos G. P. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med. 1980 Mar;68(3):356–362. doi: 10.1016/0002-9343(80)90103-5. [DOI] [PubMed] [Google Scholar]
  3. Antman K., Shemin R., Ryan L., Klegar K., Osteen R., Herman T., Lederman G., Corson J. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol. 1988 Jan;6(1):147–153. doi: 10.1200/JCO.1988.6.1.147. [DOI] [PubMed] [Google Scholar]
  4. Butchart E. G., Ashcroft T., Barnsley W. C., Holden M. P. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax. 1976 Feb;31(1):15–24. doi: 10.1136/thx.31.1.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chahinian A. P., Antman K., Goutsou M., Corson J. M., Suzuki Y., Modeas C., Herndon J. E., 2nd, Aisner J., Ellison R. R., Leone L. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol. 1993 Aug;11(8):1559–1565. doi: 10.1200/JCO.1993.11.8.1559. [DOI] [PubMed] [Google Scholar]
  6. Connelly R. R., Spirtas R., Myers M. H., Percy C. L., Fraumeni J. F., Jr Demographic patterns for mesothelioma in the United States. J Natl Cancer Inst. 1987 Jun;78(6):1053–1060. [PubMed] [Google Scholar]
  7. Dabouis G., Le Mevel B., Corroller J. Treatment of diffuse pleural malignant mesothelioma by cis dichloro diammine platinum (C.D.D.P.) in nine patients. Cancer Chemother Pharmacol. 1981;5(3):209–210. doi: 10.1007/BF00258484. [DOI] [PubMed] [Google Scholar]
  8. Dillman R. O., Seagren S. L., Propert K. J., Guerra J., Eaton W. L., Perry M. C., Carey R. W., Frei E. F., 3rd, Green M. R. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990 Oct 4;323(14):940–945. doi: 10.1056/NEJM199010043231403. [DOI] [PubMed] [Google Scholar]
  9. Enterline P. E., Henderson V. L. Geographic patterns for pleural mesothelioma deaths in the United States, 1968-81. J Natl Cancer Inst. 1987 Jul;79(1):31–37. [PubMed] [Google Scholar]
  10. Eschwege F., Schlienger M. La radiothérapie des mésothéliomes pleuraux malins. A propos de 14 cas irradiés à doses élevées. J Radiol Electrol Med Nucl. 1973 Mar;54(3):255–259. [PubMed] [Google Scholar]
  11. Falkson G., Alberts A. S., Falkson H. C. Malignant pleural mesothelioma treatment: the current state of the art. Cancer Treat Rev. 1988 Dec;15(4):231–242. doi: 10.1016/0305-7372(88)90023-0. [DOI] [PubMed] [Google Scholar]
  12. Forastiere A. A., Orringer M. B., Perez-Tamayo C., Urba S. G., Husted S., Takasugi B. J., Zahurak M. Concurrent chemotherapy and radiation therapy followed by transhiatal esophagectomy for local-regional cancer of the esophagus. J Clin Oncol. 1990 Jan;8(1):119–127. doi: 10.1200/JCO.1990.8.1.119. [DOI] [PubMed] [Google Scholar]
  13. Gerner R. E., Moore G. E. Chemotherapy of malignant mesothelioma. Oncology. 1974;30(2):152–155. doi: 10.1159/000224951. [DOI] [PubMed] [Google Scholar]
  14. Ginsberg R. J., Hill L. D., Eagan R. T., Thomas P., Mountain C. F., Deslauriers J., Fry W. A., Butz R. O., Goldberg M., Waters P. F. Modern thirty-day operative mortality for surgical resections in lung cancer. J Thorac Cardiovasc Surg. 1983 Nov;86(5):654–658. [PubMed] [Google Scholar]
  15. Gordon W., Jr, Antman K. H., Greenberger J. S., Weichselbaum R. R., Chaffey J. T. Radiation therapy in the management of patients with mesothelioma. Int J Radiat Oncol Biol Phys. 1982 Jan;8(1):19–25. doi: 10.1016/0360-3016(82)90379-0. [DOI] [PubMed] [Google Scholar]
  16. Harvey V. J., Slevin M. L., Ponder B. A., Blackshaw A. J., Wrigley P. F. Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin. Cancer. 1984 Sep 15;54(6):961–964. doi: 10.1002/1097-0142(19840915)54:6<961::aid-cncr2820540602>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  17. Law M. R., Gregor A., Hodson M. E., Bloom H. J., Turner-Warwick M. Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax. 1984 Apr;39(4):255–259. doi: 10.1136/thx.39.4.255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Law M. R., Hodson M. E., Turner-Warwick M. Malignant mesothelioma of the pleura: clinical aspects and symptomatic treatment. Eur J Respir Dis. 1984 Apr;65(3):162–168. [PubMed] [Google Scholar]
  19. McCormack P. M., Nagasaki F., Hilaris B. S., Martini N. Surgical treatment of pleural mesothelioma. J Thorac Cardiovasc Surg. 1982 Dec;84(6):834–842. [PubMed] [Google Scholar]
  20. Nauta R. J., Osteen R. T., Antman K. H., Koster J. K. Clinical staging and the tendency of malignant pleural mesotheliomas to remain localized. Ann Thorac Surg. 1982 Jul;34(1):66–70. doi: 10.1016/s0003-4975(10)60855-7. [DOI] [PubMed] [Google Scholar]
  21. Patz E. F., Jr, Shaffer K., Piwnica-Worms D. R., Jochelson M., Sarin M., Sugarbaker D. J., Pugatch R. D. Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. AJR Am J Roentgenol. 1992 Nov;159(5):961–966. doi: 10.2214/ajr.159.5.1414807. [DOI] [PubMed] [Google Scholar]
  22. Ruffie P., Feld R., Minkin S., Cormier Y., Boutan-Laroze A., Ginsberg R., Ayoub J., Shepherd F. A., Evans W. K., Figueredo A. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol. 1989 Aug;7(8):1157–1168. doi: 10.1200/JCO.1989.7.8.1157. [DOI] [PubMed] [Google Scholar]
  23. Rusch V. W., Piantadosi S., Holmes E. C. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg. 1991 Jul;102(1):1–9. [PubMed] [Google Scholar]
  24. Rusch V. W. Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma. Chest. 1993 Apr;103(4 Suppl):382S–384S. doi: 10.1378/chest.103.4_supplement.382s. [DOI] [PubMed] [Google Scholar]
  25. Rusch V. W. Trials in malignant mesothelioma. LCSG 851 and 882. Chest. 1994 Dec;106(6 Suppl):359S–362S. [PubMed] [Google Scholar]
  26. Rusch V. W., Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1996 Apr;111(4):815–826. doi: 10.1016/s0022-5223(96)70342-2. [DOI] [PubMed] [Google Scholar]
  27. Sugarbaker D. J., Mentzer S. J., Strauss G. Extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma. Ann Thorac Surg. 1992 Nov;54(5):941–946. doi: 10.1016/0003-4975(92)90654-m. [DOI] [PubMed] [Google Scholar]
  28. Sugarbaker D. J., Strauss G. M., Lynch T. J., Richards W., Mentzer S. J., Lee T. H., Corson J. M., Antman K. H. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol. 1993 Jun;11(6):1172–1178. doi: 10.1200/JCO.1993.11.6.1172. [DOI] [PubMed] [Google Scholar]
  29. Walker A. M., Loughlin J. E., Friedlander E. R., Rothman K. J., Dreyer N. A. Projections of asbestos-related disease 1980-2009. J Occup Med. 1983 May;25(5):409–425. [PubMed] [Google Scholar]
  30. Wörn H. Möglichkeiten und Ergebnisse der chirurgischen Behandlung des malign(n Pleuramesothelioms. Thoraxchir Vask Chir. 1974 Oct;22(5):391–393. doi: 10.1055/s-0028-1102795. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES